BIOL:NSD-BIOLASE, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 0.57

Change

+0.00 (+0.35)%

Market Cap

USD 0.09B

Volume

0.90M

Avg Analyst Target

USD 1.15 (+100.24%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-02 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+4.20 (+0.60%)

USD55.06B 79.31 59.42
PODD Insulet Corporation

-0.99 (-0.35%)

USD19.16B 2,202.28 159.45
ABMD Abiomed, Inc

+1.22 (+0.37%)

USD14.83B 66.22 55.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.25 (+0.30%)

USD12.46B 62.26 31.59
TNDM Tandem Diabetes Care, Inc

-2.05 (-1.89%)

USD6.81B N/A N/A
SWAV ShockWave Medical, Inc

-11.36 (-6.24%)

USD6.37B N/A N/A
IART Integra LifeSciences Holdings ..

-1.40 (-1.93%)

USD6.12B 30.06 26.83
INMD InMode Ltd

+1.14 (+1.00%)

USD4.34B 38.00 31.47
LIVN LivaNova PLC

+1.58 (+1.83%)

USD4.23B 77.40 N/A

ETFs Containing BIOL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 36.74% 64% D 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.74% 64% D 81% B-
Trailing 12 Months  
Capital Gain 36.41% 46% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 36.41% 46% F 54% F
Trailing 5 Years  
Capital Gain -91.10% 16% F 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.10% 16% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -32.19% 9% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.19% 9% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 52.70% 62% D- 34% F
Risk Adjusted Return -61.09% 10% F 4% F
Market Capitalization 0.09B 24% F 17% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.57 82% B- 52% F
Price / Cash Flow Ratio -6.73 44% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -108.65% 22% F 18% F
Return on Invested Capital -93.19% 17% F 8% F
Return on Assets -27.33% 21% F 12% F
Debt to Equity Ratio 161.41% 18% F 12% F
Technical Ratios  
Short Ratio 2.09 73% C 58% F
Short Percent 2.61% 63% D 56% F
Beta 1.45 38% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector